# A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

> **NCT04611776** · PHASE2 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04611776
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-01
- **Primary completion:** 2025-03-06
- **Final completion:** 2026-01-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The positive results from IMpower010 demonstrated benefit by adding atezolizumab as adjuvant therapy in early stage NSCLC. These results raised ethical concerns of enrolling pts to best supportive care over checkpoint inhibition in this setting.
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04611776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04611776, "A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04611776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*